(LEG) Leggett & Platt - Overview
Exchange: NYSE •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US5246601075
Stock: Steel Rod, Drawn Wire, Innersprings, Mattress Components, Automotive Seating
Total Rating 50
Risk 99
Buy Signal -0.94
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 2.12% |
| Yield on Cost 5y | 0.56% |
| Yield CAGR 5y | -41.08% |
| Payout Consistency | 66.3% |
| Payout Ratio | 24.1% |
| Risk 5d forecast | |
|---|---|
| Volatility | 48.0% |
| Relative Tail Risk | -19.3% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.66 |
| Alpha | 8.12 |
| Character TTM | |
|---|---|
| Beta | 1.202 |
| Beta Downside | 1.527 |
| Drawdowns 3y | |
|---|---|
| Max DD | 78.99% |
| CAGR/Max DD | -0.31 |
Description: LEG Leggett & Platt January 18, 2026
Leggett & Platt (NYSE: LEG) is a diversified manufacturer of engineered components for the bedding, furniture, automotive, aerospace, and industrial markets. Its product portfolio spans steel rods, innersprings, specialty foams, hydraulic cylinders, motion hardware, and soft-seating systems, serving OEMs, private-label manufacturers, big-box retailers, and e-commerce platforms worldwide.
Key operating metrics (FY 2024) show revenue of roughly $4.1 billion, an adjusted EBITDA margin near 13 %, and a free-cash-flow conversion of about 70 %-indicating solid cash generation despite cyclical exposure to the U.S. housing market. The business is sensitive to macro-drivers such as residential construction starts, consumer discretionary spending, and automotive OEM capital-expenditure cycles; a 1 % rise in U.S. home-building permits historically correlates with a ~0.3 % lift in LEG’s top-line.
For a deeper, data-rich assessment of LEG’s valuation dynamics and scenario analysis, you may find ValueRay’s platform useful as a next step in your research.
Piotroski VR‑10 (Strict, 0-10) 5.0
| Net Income: 224.4m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.08 > 0.02 and ΔFCF/TA 1.42 > 1.0 |
| NWC/Revenue: 21.92% < 20% (prev 12.67%; Δ 9.25% < -1%) |
| CFO/TA 0.10 > 3% & CFO 339.0m > Net Income 224.4m |
| Net Debt (1.20b) to EBITDA (496.1m): 2.42 < 3 |
| Current Ratio: 2.15 > 1.5 & < 3 |
| Outstanding Shares: last quarter (140.2m) vs 12m ago 1.59% < -2% |
| Gross Margin: 17.93% > 18% (prev 0.17%; Δ 1776 % > 0.5%) |
| Asset Turnover: 114.2% > 50% (prev 117.5%; Δ -3.29% > 0%) |
| Interest Coverage Ratio: 4.78 > 6 (EBITDA TTM 496.1m / Interest Expense TTM 77.7m) |
Altman Z'' 5.38
| A: 0.26 (Total Current Assets 1.71b - Total Current Liabilities 794.1m) / Total Assets 3.52b |
| B: 0.64 (Retained Earnings 2.25b / Total Assets 3.52b) |
| C: 0.10 (EBIT TTM 371.3m / Avg Total Assets 3.65b) |
| D: 0.87 (Book Value of Equity 2.22b / Total Liabilities 2.55b) |
| Altman-Z'' Score: 5.38 = AAA |
Beneish M -3.23
| DSRI: 0.95 (Receivables 568.4m/638.1m, Revenue 4.17b/4.44b) |
| GMI: 0.93 (GM 17.93% / 16.76%) |
| AQI: 0.95 (AQ_t 0.28 / AQ_t-1 0.29) |
| SGI: 0.94 (Revenue 4.17b / 4.44b) |
| TATA: -0.03 (NI 224.4m - CFO 339.0m) / TA 3.52b) |
| Beneish M-Score: -3.23 (Cap -4..+1) = AA |
What is the price of LEG shares?
As of February 07, 2026, the stock is trading at USD 12.89 with a total of 1,130,983 shares traded.
Over the past week, the price has changed by +10.45%, over one month by +10.74%, over three months by +48.46% and over the past year by +30.21%.
Over the past week, the price has changed by +10.45%, over one month by +10.74%, over three months by +48.46% and over the past year by +30.21%.
Is LEG a buy, sell or hold?
Leggett & Platt has received a consensus analysts rating of 3.00.
Therefor, it is recommend to hold LEG.
- StrongBuy: 0
- Buy: 0
- Hold: 4
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the LEG price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 12.5 | -3% |
| Analysts Target Price | 12.5 | -3% |
| ValueRay Target Price | 12.5 | -3.4% |
LEG Fundamental Data Overview February 05, 2026
P/E Trailing = 7.677
P/S = 0.4012
P/B = 1.7226
P/EG = -4.11
Revenue TTM = 4.17b USD
EBIT TTM = 371.3m USD
EBITDA TTM = 496.1m USD
Long Term Debt = 1.50b USD (from longTermDebt, last quarter)
Short Term Debt = 47.7m USD (from shortTermDebt, last quarter)
Debt = 1.66b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 1.20b USD (from netDebt column, last quarter)
Enterprise Value = 2.88b USD (1.67b + Debt 1.66b - CCE 460.7m)
Interest Coverage Ratio = 4.78 (Ebit TTM 371.3m / Interest Expense TTM 77.7m)
EV/FCF = 10.29x (Enterprise Value 2.88b / FCF TTM 279.6m)
FCF Yield = 9.72% (FCF TTM 279.6m / Enterprise Value 2.88b)
FCF Margin = 6.70% (FCF TTM 279.6m / Revenue TTM 4.17b)
Net Margin = 5.38% (Net Income TTM 224.4m / Revenue TTM 4.17b)
Gross Margin = 17.93% ((Revenue TTM 4.17b - Cost of Revenue TTM 3.42b) / Revenue TTM)
Gross Margin QoQ = 18.69% (prev 17.86%)
Tobins Q-Ratio = 0.82 (Enterprise Value 2.88b / Total Assets 3.52b)
Interest Expense / Debt = 1.11% (Interest Expense 18.5m / Debt 1.66b)
Taxrate = 17.62% (27.2m / 154.4m)
NOPAT = 305.9m (EBIT 371.3m * (1 - 17.62%))
Current Ratio = 2.15 (Total Current Assets 1.71b / Total Current Liabilities 794.1m)
Debt / Equity = 1.71 (Debt 1.66b / totalStockholderEquity, last quarter 971.8m)
Debt / EBITDA = 2.42 (Net Debt 1.20b / EBITDA 496.1m)
Debt / FCF = 4.30 (Net Debt 1.20b / FCF TTM 279.6m)
Total Stockholder Equity = 816.1m (last 4 quarters mean from totalStockholderEquity)
RoA = 6.14% (Net Income 224.4m / Total Assets 3.52b)
RoE = 27.49% (Net Income TTM 224.4m / Total Stockholder Equity 816.1m)
RoCE = 16.06% (EBIT 371.3m / Capital Employed (Equity 816.1m + L.T.Debt 1.50b))
RoIC = 11.82% (NOPAT 305.9m / Invested Capital 2.59b)
WACC = 5.64% (E(1.67b)/V(3.34b) * Re(10.34%) + D(1.66b)/V(3.34b) * Rd(1.11%) * (1-Tc(0.18)))
Discount Rate = 10.34% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 1.35%
[DCF Debug] Terminal Value 86.29% ; FCFF base≈266.3m ; Y1≈265.1m ; Y5≈278.1m
Fair Price DCF = 52.39 (EV 8.30b - Net Debt 1.20b = Equity 7.10b / Shares 135.4m; r=5.90% [WACC]; 5y FCF grow -1.12% → 2.90% )
EPS Correlation: -85.29 | EPS CAGR: -56.30% | SUE: -4.0 | # QB: 0
Revenue Correlation: -96.75 | Revenue CAGR: -6.49% | SUE: 0.41 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.25 | Chg30d=+0.000 | Revisions Net=+1 | Analysts=4
EPS next Year (2026-12-31): EPS=1.09 | Chg30d=+0.000 | Revisions Net=+1 | Growth EPS=+4.2% | Growth Revenue=-3.8%
P/S = 0.4012
P/B = 1.7226
P/EG = -4.11
Revenue TTM = 4.17b USD
EBIT TTM = 371.3m USD
EBITDA TTM = 496.1m USD
Long Term Debt = 1.50b USD (from longTermDebt, last quarter)
Short Term Debt = 47.7m USD (from shortTermDebt, last quarter)
Debt = 1.66b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 1.20b USD (from netDebt column, last quarter)
Enterprise Value = 2.88b USD (1.67b + Debt 1.66b - CCE 460.7m)
Interest Coverage Ratio = 4.78 (Ebit TTM 371.3m / Interest Expense TTM 77.7m)
EV/FCF = 10.29x (Enterprise Value 2.88b / FCF TTM 279.6m)
FCF Yield = 9.72% (FCF TTM 279.6m / Enterprise Value 2.88b)
FCF Margin = 6.70% (FCF TTM 279.6m / Revenue TTM 4.17b)
Net Margin = 5.38% (Net Income TTM 224.4m / Revenue TTM 4.17b)
Gross Margin = 17.93% ((Revenue TTM 4.17b - Cost of Revenue TTM 3.42b) / Revenue TTM)
Gross Margin QoQ = 18.69% (prev 17.86%)
Tobins Q-Ratio = 0.82 (Enterprise Value 2.88b / Total Assets 3.52b)
Interest Expense / Debt = 1.11% (Interest Expense 18.5m / Debt 1.66b)
Taxrate = 17.62% (27.2m / 154.4m)
NOPAT = 305.9m (EBIT 371.3m * (1 - 17.62%))
Current Ratio = 2.15 (Total Current Assets 1.71b / Total Current Liabilities 794.1m)
Debt / Equity = 1.71 (Debt 1.66b / totalStockholderEquity, last quarter 971.8m)
Debt / EBITDA = 2.42 (Net Debt 1.20b / EBITDA 496.1m)
Debt / FCF = 4.30 (Net Debt 1.20b / FCF TTM 279.6m)
Total Stockholder Equity = 816.1m (last 4 quarters mean from totalStockholderEquity)
RoA = 6.14% (Net Income 224.4m / Total Assets 3.52b)
RoE = 27.49% (Net Income TTM 224.4m / Total Stockholder Equity 816.1m)
RoCE = 16.06% (EBIT 371.3m / Capital Employed (Equity 816.1m + L.T.Debt 1.50b))
RoIC = 11.82% (NOPAT 305.9m / Invested Capital 2.59b)
WACC = 5.64% (E(1.67b)/V(3.34b) * Re(10.34%) + D(1.66b)/V(3.34b) * Rd(1.11%) * (1-Tc(0.18)))
Discount Rate = 10.34% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 1.35%
[DCF Debug] Terminal Value 86.29% ; FCFF base≈266.3m ; Y1≈265.1m ; Y5≈278.1m
Fair Price DCF = 52.39 (EV 8.30b - Net Debt 1.20b = Equity 7.10b / Shares 135.4m; r=5.90% [WACC]; 5y FCF grow -1.12% → 2.90% )
EPS Correlation: -85.29 | EPS CAGR: -56.30% | SUE: -4.0 | # QB: 0
Revenue Correlation: -96.75 | Revenue CAGR: -6.49% | SUE: 0.41 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.25 | Chg30d=+0.000 | Revisions Net=+1 | Analysts=4
EPS next Year (2026-12-31): EPS=1.09 | Chg30d=+0.000 | Revisions Net=+1 | Growth EPS=+4.2% | Growth Revenue=-3.8%